RU2018126811A3 - - Google Patents

Download PDF

Info

Publication number
RU2018126811A3
RU2018126811A3 RU2018126811A RU2018126811A RU2018126811A3 RU 2018126811 A3 RU2018126811 A3 RU 2018126811A3 RU 2018126811 A RU2018126811 A RU 2018126811A RU 2018126811 A RU2018126811 A RU 2018126811A RU 2018126811 A3 RU2018126811 A3 RU 2018126811A3
Authority
RU
Russia
Application number
RU2018126811A
Other languages
Russian (ru)
Other versions
RU2018126811A (ru
RU2774414C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46171913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2018126811(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2018126811A publication Critical patent/RU2018126811A/ru
Publication of RU2018126811A3 publication Critical patent/RU2018126811A3/ru
Application granted granted Critical
Publication of RU2774414C2 publication Critical patent/RU2774414C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018126811A 2010-11-30 2011-11-30 Индуцирующий цитотоксичность терапевтический агент RU2774414C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2010-266760 2010-11-30
JP2010266760 2010-11-30
JP2011121771 2011-05-31
JP2011-121771 2011-05-31
JP2011-238818 2011-10-31
JP2011238818 2011-10-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2013129694A Division RU2663123C2 (ru) 2010-11-30 2011-11-30 Индуцирующий цитотоксичность терапевтический агент

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2022110238A Division RU2824285C2 (ru) 2010-11-30 2022-04-15 Индуцирующий цитотоксичность терапевтический агент

Publications (3)

Publication Number Publication Date
RU2018126811A RU2018126811A (ru) 2019-03-13
RU2018126811A3 true RU2018126811A3 (cg-RX-API-DMAC7.html) 2019-05-07
RU2774414C2 RU2774414C2 (ru) 2022-06-21

Family

ID=

Also Published As

Publication number Publication date
KR20190028811A (ko) 2019-03-19
KR102447595B1 (ko) 2022-09-26
AU2011337697A1 (en) 2013-07-04
KR20210037755A (ko) 2021-04-06
CA2819530C (en) 2023-01-10
LT2647707T (lt) 2018-11-12
KR20130130765A (ko) 2013-12-02
EP4279513A2 (en) 2023-11-22
JP2018093879A (ja) 2018-06-21
EP4279513A3 (en) 2024-02-28
SMT202600029T1 (it) 2026-03-09
EP4279512A3 (en) 2024-02-28
US20240262933A1 (en) 2024-08-08
US11066483B2 (en) 2021-07-20
JP2025065332A (ja) 2025-04-17
SG10201506840QA (en) 2015-10-29
TW201249872A (en) 2012-12-16
KR20220082104A (ko) 2022-06-16
US12479929B2 (en) 2025-11-25
EP2647707B1 (en) 2018-09-12
EP4303236A3 (en) 2024-03-20
RS67768B1 (sr) 2026-03-31
RU2663123C2 (ru) 2018-08-01
FI3434767T3 (fi) 2026-02-12
KR102244173B1 (ko) 2021-04-26
JP6773929B2 (ja) 2020-10-21
CN103429737B (zh) 2020-07-14
TWI807362B (zh) 2023-07-01
JP2020078335A (ja) 2020-05-28
DK3434767T3 (en) 2026-02-02
RU2013129694A (ru) 2015-01-10
JP6963665B2 (ja) 2021-11-10
TW202106717A (zh) 2021-02-16
TW201940517A (zh) 2019-10-16
PT2647707T (pt) 2018-11-15
TWI709574B (zh) 2020-11-11
MX349057B (es) 2017-07-07
PL2647707T3 (pl) 2019-02-28
JP2022023133A (ja) 2022-02-07
RU2018126811A (ru) 2019-03-13
SI2647707T1 (sl) 2018-12-31
PT3434767T (pt) 2026-01-23
JP2025120308A (ja) 2025-08-15
BR112013013311A2 (pt) 2017-09-19
AR084053A1 (es) 2013-04-17
EP4303236A2 (en) 2024-01-10
JP7717435B1 (ja) 2025-08-04
SI3434767T1 (sl) 2026-04-30
JP6278598B2 (ja) 2018-02-14
JP2020202879A (ja) 2020-12-24
HRP20260101T1 (hr) 2026-03-13
EP4303237A3 (en) 2024-03-27
DK2647707T3 (en) 2018-11-19
MX2013006100A (es) 2013-07-15
HRP20181615T1 (hr) 2018-12-14
AU2017200999A1 (en) 2017-03-09
KR20240025059A (ko) 2024-02-26
US12522669B2 (en) 2026-01-13
US20140112914A1 (en) 2014-04-24
PL3434767T3 (pl) 2026-04-27
EP4303237A2 (en) 2024-01-10
EP3434767B1 (en) 2026-01-07
LT3434767T (lt) 2026-02-10
JP6719488B2 (ja) 2020-07-08
CN103429737A (zh) 2013-12-04
AU2017200999B2 (en) 2019-04-18
ES2693232T3 (es) 2018-12-10
KR101960109B1 (ko) 2019-03-20
TW201716443A (zh) 2017-05-16
EP2647707A1 (en) 2013-10-09
AU2017200565A1 (en) 2017-02-23
JPWO2012073985A1 (ja) 2014-05-19
TW202323302A (zh) 2023-06-16
US20220041756A1 (en) 2022-02-10
CN109160951A (zh) 2019-01-08
TW202140566A (zh) 2021-11-01
ES3060195T3 (en) 2026-03-25
TWI736437B (zh) 2021-08-11
SG190726A1 (en) 2013-07-31
EP2647707A4 (en) 2014-04-30
EP4279511A2 (en) 2023-11-22
JP2023115329A (ja) 2023-08-18
EP4279512A2 (en) 2023-11-22
CA2819530A1 (en) 2012-06-07
EP4279511A3 (en) 2024-01-24
TWI685503B (zh) 2020-02-21
WO2012073985A1 (ja) 2012-06-07
TWI638833B (zh) 2018-10-21
TW202604952A (zh) 2026-02-01
AU2011337697B2 (en) 2016-10-27
JP2025092666A (ja) 2025-06-19
JP7686362B1 (ja) 2025-06-02
EP3434767A1 (en) 2019-01-30
HK1259128A1 (zh) 2019-11-22
US20240294672A1 (en) 2024-09-05
TR201815863T4 (tr) 2018-11-21

Similar Documents

Publication Publication Date Title
BR112012030039A2 (cg-RX-API-DMAC7.html)
BR112012028408A2 (cg-RX-API-DMAC7.html)
BR112012029986A2 (cg-RX-API-DMAC7.html)
BR112012027808A2 (cg-RX-API-DMAC7.html)
BR112012024897A2 (cg-RX-API-DMAC7.html)
BR112012026492A2 (cg-RX-API-DMAC7.html)
BR112012031500A2 (cg-RX-API-DMAC7.html)
BR112012002126A2 (cg-RX-API-DMAC7.html)
BR112012026946A2 (cg-RX-API-DMAC7.html)
BR112012025482A2 (cg-RX-API-DMAC7.html)
BR112013006400A2 (cg-RX-API-DMAC7.html)
BR112012031826A2 (cg-RX-API-DMAC7.html)
BR112012025577A2 (cg-RX-API-DMAC7.html)
BR112012023249A2 (cg-RX-API-DMAC7.html)
BR112012028186A2 (cg-RX-API-DMAC7.html)
BR112012027015A2 (cg-RX-API-DMAC7.html)
BR112012025308A2 (cg-RX-API-DMAC7.html)
BR112012027945A2 (cg-RX-API-DMAC7.html)
BR112012026403A2 (cg-RX-API-DMAC7.html)
BR112012024872A2 (cg-RX-API-DMAC7.html)
BR112012023265A2 (cg-RX-API-DMAC7.html)
BR112013003284A2 (cg-RX-API-DMAC7.html)
BR112013002646A2 (cg-RX-API-DMAC7.html)
BR112012022788A2 (cg-RX-API-DMAC7.html)
BR112012016895A2 (cg-RX-API-DMAC7.html)